Overview

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Status:
Not yet recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The primary objective is to determine the effect of relacorilant on the pharmacokinetics (PK) of the sensitive P-glycoprotein (P-gp) substrate dabigatran etexilate.

Phase:

Phase 1

Details

Lead Sponsor:

Corcept Therapeutics

Treatments:

Dabigatran